Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ambrosia Biosciences has raised $100.0M in total funding. The most recent round was Series B. The last funding was announced in March 2026.
Ambrosia Biosciences's investors include Janus Henderson Investors, Samsara BioCapital, Blue Owl, Redmile Group, Merck.
Ambrosia Biosciences is headquartered in Boulder, United States.
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ambrosia Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ambrosia Biosciences — Funding & Investors." VCBacked, March 31, 2026, https://www.vcbacked.co/company/ambrosia-biosciences. Accessed November 13, 2026.
VCBacked. (2026). Ambrosia Biosciences — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/ambrosia-biosciences
{{cite web |title=Ambrosia Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/ambrosia-biosciences |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Ambrosia Biosciences? Request a listing update